Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells

Thromb Haemost. 1997 Jun;77(6):1189-95.

Abstract

Angiotensin converting enzyme inhibitors (ACE-I) have been reported to prevent the recurrence of cardiovascular events. The mechanism of this decrease, however, can not be completely explained by anti-hypertensive and anti-hypertrophic effects of ACE-I. To investigate the mechanism of this decrease, we studied the regulation of plasminogen activator inhibitor-1 (PAI-1), tissue type plasminogen activator (TPA), tissue factor (TF), and tissue factor pathway inhibitor (TFPI) by angiotensin II (Ang II) in cultured rat aortic endothelial cells. Ang II increased PAI-1 and TF mRNA expression without affecting that of TPA or TFPI. These inductions were accompanied by increases in PAI-1 and TF activities and were inhibited by a type I Ang II receptor antagonist. The results suggest that Ang II decreases the antithrombotic properties of endothelial cells which increases the chance of thrombosis. Thus, inhibition of the renin-angiotensin system may be beneficial to prevent thrombus formation in treatment of ischemic heart disease.

MeSH terms

  • Angiotensin II / pharmacology*
  • Animals
  • Aorta / metabolism
  • Cells, Cultured
  • Endothelium, Vascular / metabolism*
  • Male
  • Plasminogen Activator Inhibitor 1 / metabolism*
  • RNA, Messenger / analysis
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects*
  • Thromboplastin / metabolism*
  • Vasoconstrictor Agents / pharmacology*

Substances

  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Vasoconstrictor Agents
  • Angiotensin II
  • Thromboplastin